STU3 Candidate

This page is part of the FHIR Specification (v1.8.0: STU 3 Draft). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3

4.3.2.1070 HL7 v3 Code System substanceAdminSubstitution

This code system (http://hl7.org/fhir/v3/substanceAdminSubstitution) is defined as part of HL7 v3.

Summary

Defining URL:http://hl7.org/fhir/v3/substanceAdminSubstitution
Name:v3 Code System substanceAdminSubstitution
Definition: Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.
OID:2.16.840.1.113883.5.1070 (for OID based terminology systems)
Source ResourceXML / JSON

This Code system is used in the following value sets:

4.3.2.1070.1 Code System Content

Release Date: 2016-11-11

LevelCodeDisplayDefinition
1(_ActSubstanceAdminSubstitutionCode) Abstract  Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
2  E equivalent Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
3    EC equivalent composition Description:
Substitution occurred or is permitted with another product that is a:
pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples:
Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
4      BC brand composition Description:
Substitution occurred or is permitted between equivalent Brands but not Generics
Examples:
Zestril for Prinivil Coumadin for Jantoven
4      G generic composition Description: Substitution occurred or is permitted between equivalent Generics but not Brands
Examples:
Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
3    TE therapeutic alternative Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.
Examples:
ranitidine for Tagamet
4      TB therapeutic brand Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics
> Examples:
Zantac for Tagamet
4      TG therapeutic generic Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands
> Examples:
Ranitidine for cimetidine
2  F formulary Description: This substitution was performed or is permitted based on formulary guidelines.
2  N none No substitution occurred or is permitted.